{"nctId":"NCT01617434","briefTitle":"The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes","startDateStruct":{"date":"2012-09"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":451,"armGroups":[{"label":"Liraglutide","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"liraglutide","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes for at least 180 days prior to screening and treated with stable basal insulin analogue dose of minimum 20 U/day with or without stable metformin equal to or above 1500 mg/day for at least 8 weeks prior to screening (defined as insulin adjustments less than 10% during the past 8 weeks as assessed by the investigator)\n* HbA1c (glycosylated haemoglobin A1c) 7.0-10.0% (both inclusive)\n* Body mass index (BMI) 20-45 kg/m\\^2 (both inclusive)\n\nExclusion Criteria:\n\n* Female of child-bearing potential who is pregnant, breast-feeding or intending to become pregnant\n* Recurrent severe hypoglycaemic episodes or hypoglycaemic unawareness\n* Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria in a period of 12 weeks prior to screening\n* Impaired liver or renal function\n* Uncontrolled treated or untreated hypertension (systolic blood pressure (SBP) equal to or above 180 mmHg and/or diastolic blood pressure (DBP) equal to or above 100 mmHg)\n* Any clinically significant disorder, except for conditions associated with type 2 diabetes history which in the investigator's opinion could interfere with results of the trial\n* Known or suspected abuse of alcohol or narcotics","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26","description":"The estimated mean change from baseline in HbA1c after 26 weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.30","spread":"1.015"},{"groupId":"OG001","value":"-0.11","spread":"1.088"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26","description":"The estimated mean change from baseline in FPG after 26 weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.44","spread":"2.494"},{"groupId":"OG001","value":"-0.16","spread":"3.006"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Self-Measured Plasma Glucose (SMPG) of 7-Point Profile From Baseline to Week 26","description":"The estimated mean change from baseline in mean SMPG of 7-point profile (7-points were before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime) after 26 weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.61","spread":"2.248"},{"groupId":"OG001","value":"-1.02","spread":"3.061"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline to Week 26","description":"The estimated mean change in body weight after 26 weeks of treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.54","spread":"3.669"},{"groupId":"OG001","value":"-0.42","spread":"3.909"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Achieving HbA1c Below 7.0% (American Diabetes Association [ADA] Target)","description":"Number of subjects achieving HbA1c below 7.0% (American Diabetes Association \\[ADA\\] target) after 26 weeks of treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.24","spread":null},{"groupId":"OG001","value":"14.02","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Achieving HbA1c Below or Equal to 6.5% (American Association of Clinical Endocrinologists [AACE] Target)","description":"Number of subjects achieving HbA1c below or equal to 6.5% (American Association of Clinical Endocrinologists \\[AACE\\] target) after 26 weeks of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.91","spread":null},{"groupId":"OG001","value":"3.60","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events (AEs) During The Randomised Treatment Period","description":"An AE was defined as treatment emergent if the onset date (or increase in severity) was on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. The adverse events were categorised as 'serious' and 'non-serious' adverse events. Adverse events were also categorised according to the severity as 'mild', 'moderate' and 'severe' adverse events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4918","spread":null},{"groupId":"OG001","value":"3737","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"169","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1274","spread":null},{"groupId":"OG001","value":"1060","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3474","spread":null},{"groupId":"OG001","value":"2575","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Minor Hypoglycaemic Episodes During The Randomised Treatment Period","description":"A minor hypoglycaemic episode was defined as either, (a) an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \\<2.8 mmol/L (50 mg/dL) or plasma glucose \\<3.1 mmol/L (56 mg/dL) that was handled by the subject him/herself or (b) any asymptomatic blood glucose value \\<2.8 mmol/L (50 mg/dL) or plasma glucose value \\<3.1 mmol/L (56 mg/dL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Severe Hypoglycaemic Episodes During The Randomised Treatment Period","description":"Severe hypoglycaemia episode was defined as an episode requiring assistance of another person to actively administer carbohydrate, glucagon or other resuscitative actions.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":225},"commonTop":["Nausea","Diarrhoea","Nasopharyngitis","Decreased appetite","Influenza"]}}}